Navigation Links
Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
Date:8/31/2012

THE WOODLANDS, Texas, Aug. 31, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur Sands, M.D., Ph.D., President and Chief Executive Officer, will present at the Stifel Nicolaus 2012 Healthcare Conference on Thursday, September 6, at 10:20 a.m. EST in Boston, Massachusetts. Dr. Sands will provide an overview of Lexicon's clinical development programs and milestones.

A webcast of the presentation will be available through Lexicon´s website at www.lexpharma.com. An archived version of the presentation will be available at www.lexpharma.com until October 6, 2012.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has four drug programs in mid-stage development for diabetes, carcinoid syndrome, irritable bowel syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon to Provide First Quarter 2012 Financial Results
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
3. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
4. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
5. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
6. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
8. Lexicon to Provide Second Quarter 2012 Financial Results
9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
10. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
11. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... MONTREAL , May 4, 2017  Fortuna Fix Inc. (" ... aiming to be the first to eliminate the need for ... autologous cells to treat neurodegenerative diseases. Fortuna ... ("SAB") with Professor Michael Fehlings , MD, PhD; Father ... Hack , MD, MPH; and Professor James Giordano , ...
(Date:5/4/2017)... and SAN DIEGO , May 4, ... (ACOG) 2017 Annual Clinical and Scientific Meeting— OBP Medical ... medical devices, today announced the launch of a new ... OfficeSPEC and ER-SPEC vaginal specula. Already ... extra-small and extra-large sizes makes OBP Medical,s line of ...
(Date:5/4/2017)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ... clinical grade hypothermic storage and cryopreservation ... that the Company,s first quarter 2017 financial results will ... 2017, and that the Company will host a conference ... afternoon. Management will provide an overview of the Company,s ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... May 23, 2017 , ... The Gallery of ... Sadati, is pleased to announce a new treatment option called Vivace Microneedling. This ... face, neck, and body through a virtually pain-free, non-surgical treatment. Vivace Microneedling combines ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... Specialists, are educating patients on peri-implantitis in Las Vegas, NV, and ... receive a custom gum disease consultation and leading care for peri-implantitis, with or ...
(Date:5/23/2017)... ... 2017 , ... Diagnotes, an Indianapolis-based digital healthcare communication company, ... secure clinical communication platform. The platform allows clinicians to easily escalate their preferred ... urgency of a situation. , “We know from our daily lives that ...
(Date:5/23/2017)... ... ... Orbita’s Nathan Treloar will discuss the role of voice-powered healthcare applications during ... Health and IoT: Technology Innovators and Disruption , the workshop is part of ... and consulting firm specializing in emerging consumer technology products and services. , Orbita, ...
(Date:5/23/2017)... ... May 23, 2017 , ... New ... the SPEED System™ Orthodontics, with or without a referral, from the multi-specialty Dr. ... Segundo, CA, who is skilled in providing patients with the custom, convenient and ...
Breaking Medicine News(10 mins):